201 related articles for article (PubMed ID: 32500660)
1. Management of adult patients with severe atopic dermatitis treated with dupilumab during COVID-19 pandemic: A single-center real-life experience.
Rossi M; Rovati C; Arisi M; Soglia S; Calzavara-Pinton P
Dermatol Ther; 2020 Jul; 33(4):e13765. PubMed ID: 32500660
[No Abstract] [Full Text] [Related]
2. Safety of dupilumab in severe atopic dermatitis and infection of Covid-19: two case reports.
Ferrucci S; Romagnuolo M; Angileri L; Berti E; Tavecchio S
J Eur Acad Dermatol Venereol; 2020 Jul; 34(7):e303-e304. PubMed ID: 32330323
[No Abstract] [Full Text] [Related]
3. Assessing the risk of dupilumab use for atopic dermatitis during the COVID-19 pandemic.
Kearns DG; Uppal S; Chat VS; Wu JJ
J Am Acad Dermatol; 2020 Sep; 83(3):e251-e252. PubMed ID: 32534081
[No Abstract] [Full Text] [Related]
4. Patient-Driven Discontinuation of Dupilumab During the COVID-19 Pandemic in Two Academic Hospital Clinics at the University of Toronto.
Georgakopoulos JR; Yeung J
J Cutan Med Surg; 2020; 24(4):422-423. PubMed ID: 32434413
[No Abstract] [Full Text] [Related]
5. SARS-CoV-2 asymptomatic infection in a patient under treatment with dupilumab.
Caroppo F; Biolo G; Belloni Fortina A
J Eur Acad Dermatol Venereol; 2020 Aug; 34(8):e368. PubMed ID: 32386431
[No Abstract] [Full Text] [Related]
6. Dupilumab and COVID-19: What should we expect?
Patruno C; Stingeni L; Fabbrocini G; Hansel K; Napolitano M
Dermatol Ther; 2020 Jul; 33(4):e13502. PubMed ID: 32362061
[TBL] [Abstract][Full Text] [Related]
7. COVID-19, quarantine, and atopic dermatitis.
Patruno C; Nisticò SP; Fabbrocini G; Napolitano M
Med Hypotheses; 2020 Oct; 143():109852. PubMed ID: 32447099
[No Abstract] [Full Text] [Related]
8. Atopic dermatitis in adolescents: Effectiveness and safety of dupilumab in a 16-week real-life experience during the COVID-19 pandemic in Italy.
Stingeni L; Hansel K; Antonelli E; Bello GD; Patruno C; Napolitano M; Fabbrocini G; Grieco T; Pellacani G; Fargnoli MC; Esposito M; Piras V; Zucca M; Girolomoni G
Dermatol Ther; 2021 Sep; 34(5):e15035. PubMed ID: 34152670
[TBL] [Abstract][Full Text] [Related]
9. COVID-19 in a patient with severe chronic rhinosinusitis with nasal polyps during therapy with dupilumab.
Förster-Ruhrmann U; Szczepek AJ; Bachert C; Olze H
J Allergy Clin Immunol; 2020 Jul; 146(1):218-220.e2. PubMed ID: 32417136
[No Abstract] [Full Text] [Related]
10. No evidence of increased risk for Coronavirus Disease 2019 (COVID-19) in patients treated with Dupilumab for atopic dermatitis in a high-epidemic area - Bergamo, Lombardy, Italy.
Carugno A; Raponi F; Locatelli AG; Vezzoli P; Gambini DM; Di Mercurio M; Robustelli Test E; Sena P
J Eur Acad Dermatol Venereol; 2020 Sep; 34(9):e433-e434. PubMed ID: 32339362
[No Abstract] [Full Text] [Related]
11. COVID-19 in an elderly patient treated with secukinumab.
Di Lernia V; Bombonato C; Motolese A
Dermatol Ther; 2020 Jul; 33(4):e13580. PubMed ID: 32406078
[No Abstract] [Full Text] [Related]
12. Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on ocrelizumab during the pandemic.
Ghajarzadeh M; Mirmosayyeb O; Barzegar M; Nehzat N; Vaheb S; Shaygannejad V; Maghzi AH
Mult Scler Relat Disord; 2020 Aug; 43():102222. PubMed ID: 32464586
[No Abstract] [Full Text] [Related]
13. Updates on treatment guidelines for psoriasis, atopic dermatitis (eczema), hidradenitis suppurativa, and acne/rosacea during the COVID-19 pandemic.
Yim RM; Singh I; Armstrong AW
Dermatol Online J; 2020 Oct; 26(10):. PubMed ID: 33147660
[TBL] [Abstract][Full Text] [Related]
14. Susceptibility and severity of COVID-19 in patients treated with bDMARDS and tsDMARDs: a population-based study.
Salvarani C; Bajocchi G; Mancuso P; Galli E; Muratore F; Boiardi L; Catanoso M; Pipitone N; Cassone G; Girolimetto N; Croci S; Cimino L; Gradellini F; Beltrami M; Di Lernia V; Dolci G; Massari M; Marata AM; Costantini M; Giorgi Rossi P
Ann Rheum Dis; 2020 Jul; 79(7):986-988. PubMed ID: 32467245
[No Abstract] [Full Text] [Related]
15. Lessons from the Italian COVID-19 frontline.
Bellan M; Sainaghi PP; Gavelli F; Patrucco F; Avanzi GC; Pirisi M; Castello LM
Minerva Med; 2020 Aug; 111(4):303-305. PubMed ID: 33032392
[No Abstract] [Full Text] [Related]
16. European Task Force on Atopic Dermatitis statement on severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection and atopic dermatitis.
Wollenberg A; Flohr C; Simon D; Cork MJ; Thyssen JP; Bieber T; de Bruin-Weller MS; Weidinger S; Deleuran M; Taieb A; Paul C; Trzeciak M; Werfel T; Seneschal J; Barbarot S; Darsow U; Torrelo A; Stalder JF; Svensson Å; Hijnen D; Gelmetti C; Szalai Z; Gieler U; De Raeve L; Kunz B; Spuls P; von Kobyletzki LB; Fölster-Holst R; Chernyshov PV; Christen-Zaech S; Heratizadeh A; Ring J; Vestergaard C
J Eur Acad Dermatol Venereol; 2020 Jun; 34(6):e241-e242. PubMed ID: 32223003
[No Abstract] [Full Text] [Related]
17. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy.
Grasselli G; Zangrillo A; Zanella A; Antonelli M; Cabrini L; Castelli A; Cereda D; Coluccello A; Foti G; Fumagalli R; Iotti G; Latronico N; Lorini L; Merler S; Natalini G; Piatti A; Ranieri MV; Scandroglio AM; Storti E; Cecconi M; Pesenti A;
JAMA; 2020 Apr; 323(16):1574-1581. PubMed ID: 32250385
[TBL] [Abstract][Full Text] [Related]
18. Cutaneous lupus erythematosus patients in a high-epidemic COVID-19 area, Bergamo, Italy.
Vezzoli P; Di Mercurio M; Carugno A; Gambini DM; Robustelli Test E; Imberti G; Castagna AF; Sena P
Dermatol Ther; 2020 Jul; 33(4):e13776. PubMed ID: 32506525
[No Abstract] [Full Text] [Related]
19. Teledermatologic monitoring for chronic cutaneous autoimmune diseases with smartworking during COVID-19 emergency in a tertiary center in Italy.
Brunasso AMG; Massone C
Dermatol Ther; 2020 Jul; 33(4):e13495. PubMed ID: 32458588
[TBL] [Abstract][Full Text] [Related]
20. COVID-19 Symptoms Are Attenuated in Moderate-to-Severe Atopic Dermatitis Patients Treated with Dupilumab.
Ungar B; Glickman JW; Golant AK; Dubin C; Marushchak O; Gontzes A; Mikhaylov D; Singer GK; Baum D; Wei N; Sanin A; Gruenstein D; Lebwohl MG; Pavel AB; Guttman-Yassky E
J Allergy Clin Immunol Pract; 2022 Jan; 10(1):134-142. PubMed ID: 34737108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
